Ji An Hwang1, Joon Seon Song2, Dae Yeul Yu3, Hyeong Ryul Kim4, Hye Jin Park2, Young Soo Park2, Woo Sung Kim1, Chang Min Choi1. 1. Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine Seoul, Korea. 2. Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine Seoul, Korea. 3. Disease Model Research Laboratory, Aging Research Center, Korea Research Institute of Bioscience and Biotechnology Daejeon, Korea ; Department of Functional Genomics, University of Science and Technology Daejeon, Korea. 4. Department of Thoracic Surgery, Asan Medical Center, University of Ulsan College of Medicine Seoul, Korea.
Abstract
OBJECTIVES: Peroxiredoxin 4 (Prx 4) is a newly emerging antioxidant protein that has been studied in several human cancers. Recently, it was revealed that Prx 4 is highly expressed in human lung cancer and is needed for the promotion of lung cancer progression in vitro. However, there are no clinical data regarding the association of Prx 4 and prognosis in lung cancer. MATERIALS AND METHODS: The Prx 4 expression state as a prognostic indicator was assessed by immunohistochemical staining in 142 patients with stage II non-small cell lung cancer (NSCLC) who had undergone curative surgery between 2006 and 2010. The association between the degree of Prx 4 expression and several clinicopathologic parameters was then evaluated by statistical analyses. RESULTS: The degree of Prx 4 expression was associated with histology and recurrence in the overall NSCLC patient group, with the proportion of patients with positive Prx 4 expression significantly higher for the adenocarcinoma subtype (39/70, 56%) than the squamous cell carcinoma subtype (23/72, 32%) (P = 0.004). However, when subgroup analyses according to histopathology were performed in terms of recurrence, positive Prx 4 expression was significantly correlated with higher recurrence rates (P = 0.003) and shorter disease-free survival (DFS) (P = 0.003, hazard ratio = 3.910) in patients with squamous cell carcinoma. In contrast, no meaningful relationship was observed between the level of Prx 4 expression and DFS in the adenocarcinoma subgroup. CONCLUSION: Positive Prx 4 expression is significantly correlated with recurrence and shorter DFS in patients with early-stage lung squamous cell carcinoma.
OBJECTIVES:Peroxiredoxin 4 (Prx 4) is a newly emerging antioxidant protein that has been studied in several humancancers. Recently, it was revealed that Prx 4 is highly expressed in humanlung cancer and is needed for the promotion of lung cancer progression in vitro. However, there are no clinical data regarding the association of Prx 4 and prognosis in lung cancer. MATERIALS AND METHODS: The Prx 4 expression state as a prognostic indicator was assessed by immunohistochemical staining in 142 patients with stage II non-small cell lung cancer (NSCLC) who had undergone curative surgery between 2006 and 2010. The association between the degree of Prx 4 expression and several clinicopathologic parameters was then evaluated by statistical analyses. RESULTS: The degree of Prx 4 expression was associated with histology and recurrence in the overall NSCLCpatient group, with the proportion of patients with positive Prx 4 expression significantly higher for the adenocarcinoma subtype (39/70, 56%) than the squamous cell carcinoma subtype (23/72, 32%) (P = 0.004). However, when subgroup analyses according to histopathology were performed in terms of recurrence, positive Prx 4 expression was significantly correlated with higher recurrence rates (P = 0.003) and shorter disease-free survival (DFS) (P = 0.003, hazard ratio = 3.910) in patients with squamous cell carcinoma. In contrast, no meaningful relationship was observed between the level of Prx 4 expression and DFS in the adenocarcinoma subgroup. CONCLUSION: Positive Prx 4 expression is significantly correlated with recurrence and shorter DFS in patients with early-stage lung squamous cell carcinoma.
Authors: Joan H Schiller; David Harrington; Chandra P Belani; Corey Langer; Alan Sandler; James Krook; Junming Zhu; David H Johnson Journal: N Engl J Med Date: 2002-01-10 Impact factor: 91.245
Authors: Judy B de Haan; Cecile Bladier; Mehrnoush Lotfi-Miri; Juliet Taylor; Paul Hutchinson; Peter J Crack; Paul Hertzog; Ismail Kola Journal: Free Radic Biol Med Date: 2004-01-01 Impact factor: 7.376
Authors: Peeter Karihtala; Anne Mäntyniemi; Sang Won Kang; Vuokko L Kinnula; Ylermi Soini Journal: Clin Cancer Res Date: 2003-08-15 Impact factor: 12.531
Authors: Siri T Lehtonen; Anne-Mari Svensk; Ylermi Soini; Paavo Pääkkö; Pasi Hirvikoski; Sang Won Kang; Marjaana Säily; Vuokko L Kinnula Journal: Int J Cancer Date: 2004-09-10 Impact factor: 7.396
Authors: Guoan Chen; Tarek G Gharib; Chiang-Ching Huang; Dafydd G Thomas; Kerby A Shedden; Jeremy M G Taylor; Sharon L R Kardia; David E Misek; Thomas J Giordano; Mark D Iannettoni; Mark B Orringer; Samir M Hanash; David G Beer Journal: Clin Cancer Res Date: 2002-07 Impact factor: 12.531
Authors: Evan A Elko; Brian Cunniff; David J Seward; Shi Biao Chia; Reem Aboushousha; Cheryl van de Wetering; Jos van der Velden; Allison Manuel; Arti Shukla; Nicholas H Heintz; Vikas Anathy; Albert van der Vliet; Yvonne M W Janssen-Heininger Journal: Antioxid Redox Signal Date: 2019-04-05 Impact factor: 8.401